Acute myeloid leukemia therapeutics: CARs in the driver’s seat

Acute myeloid leukemia remains a difficult disease to cure and novel therapeutic approaches are needed. To this end, we developed CD123 chimeric antigen receptor (CAR) redirected T cells which exhibited potent antileukemic activity. We discuss what we learned during the development of CD123 CARs and...

Descripción completa

Detalles Bibliográficos
Autores principales: Mardiros, Armen, Brown, Christine E, Budde, L Elizabeth, Wang, Xiuli, Forman, Stephen J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3916356/
https://www.ncbi.nlm.nih.gov/pubmed/24511454
http://dx.doi.org/10.4161/onci.27214
_version_ 1782302698643652608
author Mardiros, Armen
Brown, Christine E
Budde, L Elizabeth
Wang, Xiuli
Forman, Stephen J
author_facet Mardiros, Armen
Brown, Christine E
Budde, L Elizabeth
Wang, Xiuli
Forman, Stephen J
author_sort Mardiros, Armen
collection PubMed
description Acute myeloid leukemia remains a difficult disease to cure and novel therapeutic approaches are needed. To this end, we developed CD123 chimeric antigen receptor (CAR) redirected T cells which exhibited potent antileukemic activity. We discuss what we learned during the development of CD123 CARs and future directions for this immunotherapy.
format Online
Article
Text
id pubmed-3916356
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-39163562014-02-07 Acute myeloid leukemia therapeutics: CARs in the driver’s seat Mardiros, Armen Brown, Christine E Budde, L Elizabeth Wang, Xiuli Forman, Stephen J Oncoimmunology Author's View Acute myeloid leukemia remains a difficult disease to cure and novel therapeutic approaches are needed. To this end, we developed CD123 chimeric antigen receptor (CAR) redirected T cells which exhibited potent antileukemic activity. We discuss what we learned during the development of CD123 CARs and future directions for this immunotherapy. Landes Bioscience 2013-12-01 2013-12-09 /pmc/articles/PMC3916356/ /pubmed/24511454 http://dx.doi.org/10.4161/onci.27214 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Mardiros, Armen
Brown, Christine E
Budde, L Elizabeth
Wang, Xiuli
Forman, Stephen J
Acute myeloid leukemia therapeutics: CARs in the driver’s seat
title Acute myeloid leukemia therapeutics: CARs in the driver’s seat
title_full Acute myeloid leukemia therapeutics: CARs in the driver’s seat
title_fullStr Acute myeloid leukemia therapeutics: CARs in the driver’s seat
title_full_unstemmed Acute myeloid leukemia therapeutics: CARs in the driver’s seat
title_short Acute myeloid leukemia therapeutics: CARs in the driver’s seat
title_sort acute myeloid leukemia therapeutics: cars in the driver’s seat
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3916356/
https://www.ncbi.nlm.nih.gov/pubmed/24511454
http://dx.doi.org/10.4161/onci.27214
work_keys_str_mv AT mardirosarmen acutemyeloidleukemiatherapeuticscarsinthedriversseat
AT brownchristinee acutemyeloidleukemiatherapeuticscarsinthedriversseat
AT buddelelizabeth acutemyeloidleukemiatherapeuticscarsinthedriversseat
AT wangxiuli acutemyeloidleukemiatherapeuticscarsinthedriversseat
AT formanstephenj acutemyeloidleukemiatherapeuticscarsinthedriversseat

Ejemplares similares